Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADK | P55263 | 1/20 | 0.34 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.31 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19379661 | 1.00 | ADK (0.34) | ADKRETKDRSLC29A1POLB | |
| SCHEMBL19379637 | 0.76 | ADK (0.36) | ADKRETKDRPOLBPRMT5 | |
| SCHEMBL19397141 | 0.76 | ADK (0.36) | ADKRETKDRPOLBPRMT5 | |
| SCHEMBL19397144 | 0.73 | ADK (0.38) | ADKRETKDRPRMT5WDR77 | |
| SCHEMBL30745131 | 0.73 | ADK (0.38) | ADKRETKDRPRMT5WDR77 | |
| SCHEMBL19379658 | 0.73 | ADK (0.38) | ADKRETKDRPRMT5WDR77 | |
| SCHEMBL15960600 | 0.72 | ADORA3 (0.56) | ADKPRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL31154632 | 0.72 | ADORA3 (0.56) | ADKPRMT5WDR77ADORA3ADORA1 | |
| SCHEMBL19379649 | 0.71 | ADK (0.42) | ADKPOLBADORA3ADORA1METTL3 | |
| SCHEMBL19379648 | 0.71 | ADK (0.42) | ADKPOLBADORA3ADORA1METTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4292658-A2 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | Novartis AG (CH) | 2023-12-20 | — | — | EP | disclosed |
| EP-3433257-B1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2019-10-01 | — | — | US | disclosed |
| EP-3433257-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | Novartis AG (CH) | 2019-01-30 | — | — | EP | disclosed |
| US-20180258129-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2018-09-13 | — | — | US | disclosed |
| US-9988416-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS INSTITUTE FOR TROPICAL DISEASES PTE LTD (SG) | 2017-09-28 | — | — | US | disclosed |
| WO-2017163186-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | NOVARTIS AG (CH) | 2017-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275329-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | ADK 578/4885RET 2883/4885KDR 3502/4885 |
| US-20180258129-A1 | ALKYNYL NUCLEOSIDE ANALOGS AS INHIBITORS OF HUMAN RHINOVIRUS | RNASEH1, ENTPD5, SARNP | ADK 578/4885RET 2883/4885KDR 3502/4885 |
| US-10428105-B2 | Alkynyl nucleoside analogs as inhibitors of human rhinovirus | RNASEH1, ENTPD5, SARNP | ADK 578/4885RET 2883/4885KDR 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.